Healthcare Cybersecurity: Protecting Connected Care Delivery
In healthcare and life sciences, cyber risk sits directly inside the operating model. It shapes how care is delivered, how research is protected, how reimbursement flows, and how trust is sustained when digital infrastructure is under pressure.
Healthcare cybersecurity has traditionally focused on privacy, HIPAA compliance, and breach prevention. These remain essential, but leaders now need a broader measure of readiness: whether the organization can sustain critical operations when digital systems are impaired. An organization may recover from exposed records, but not as easily from an event that disrupts emergency care, disables clinical systems, blocks payments, compromises trial integrity, or exposes sensitive research.
For C-level leaders, the defining question is no longer simply, “Are we secure?” It is, “Can we continue delivering safe, trusted care when our digital ecosystem is degraded, compromised, or unavailable?” That reframes cyber resilience as an enterprise operating capability—not solely a technology function. Compliance establishes the baseline; resilience is demonstrated by the ability to protect patients, preserve trust, and sustain critical operations during disruption.
The next era of healthcare IT resilience will be defined not by technology recovery alone, but by the ability to protect patients, preserve trust, and sustain critical operations under digital stress.
Cyber Risk in Healthcare Is Now Care Delivery Risk
Digital disruption has reached directly into clinical operations for years. What has changed is the scale, frequency, and systemic nature of the risk. Ransomware, identity compromise, vendor outages, data theft, cloud disruption, and system intrusion can now affect patient admissions, prescriptions, lab results, imaging, billing, and crisis response.
That makes cyber resilience a patient safety issue.
Nearly three in four U.S. healthcare organizations experiencing cyberattacks reported disruption to patient care. Reported impacts included delayed procedures and tests, longer patient stays, complications from medical procedures, and concerns about patient outcomes.
The Change Healthcare cyberattack exposed a critical dependency in modern care delivery: healthcare operations now rely on shared digital infrastructure that extends far beyond the hospital or health system. What began as a cyber incident became a national-scale disruption to care access, payment flows, provider finances, and administrative continuity.
In a survey of nearly 1,000 hospitals, 74% reported direct patient care impact, and nearly 40% reported patients having difficulty accessing care because of delays in utilization requirements such as prior authorization. The same analysis cited a $6.3 billion drop in claims submitted across affected hospital and physician clients in the first three weeks after the attack.
The lesson is not simply that third-party platforms create risk. It is that care delivery now depends on an ecosystem of claims platforms, clearinghouses, scheduling applications, identity systems, cloud services, vendors, payment rails, and workflows that often sit outside each organization’s direct control.
Healthcare leaders must identify the pathways that keep care moving. Which systems are required to admit patients? Which platforms authorize treatment? Which data flows support pharmacies, labs, imaging, and care teams? Which third-party failures would create bottlenecks within hours?
At the board level, cyber exposure must be translated into operational consequences: deferred care, emergency department diversion, delayed diagnoses, manual medication reconciliation, interrupted revenue cycle, staff overload, regulatory reporting, and reputational loss.
Key Takeaway
Cyber risk in healthcare should be measured not only by records exposed or systems encrypted, but by its potential to delay care, disrupt clinical workflows, strain staff, interrupt cash flow, and compromise patient safety and trust at the point of care.
Explore Our Healthcare & Life Sciences Consulting Services
P&C Global’s healthcare and life sciences practice partners with leading health systems and innovators.
Why Healthcare Cybersecurity Needs a New Model
Healthcare and life sciences organizations need the same foundational cybersecurity controls as other sectors: identity management, endpoint protection, network monitoring, segmentation, vulnerability management, incident response, backup testing, and security awareness. What distinguishes the sector is the proximity of cyber failure to patient safety, continuity of care, and research integrity.
Those controls must therefore be applied around the realities of healthcare operations: clinical workflows, patient safety protocols, medical device governance, revenue cycle continuity, research environments, and third-party care dependencies. Financial exposure is common across cyber incidents, but in healthcare the impact can move quickly from balance sheet to bedside. Disrupted reimbursement, claims processing, or prior authorization can affect provider liquidity, patient access, and the organization’s ability to keep care moving.
This is why compliance-led healthcare cybersecurity is insufficient. HIPAA compliance, privacy rules, and regulatory obligations remain foundational, but they do not answer the more urgent question: can care continue safely when systems fail? This shift is reflected across major healthcare markets. U.S. Healthcare and Public Health Cybersecurity Performance Goals connect cyber preparedness to patient safety; Europe’s NIS2 Directive expands cybersecurity obligations across critical sectors, including healthcare; and the U.K.’s NHS Data Security and Protection Toolkit requires organizations with access to NHS patient data and systems to assess performance against national data security standards.
A healthcare-specific resilience model must address clinical downtime design, patient safety impacts, medical device lifecycle security, emergency access, vendor dependencies, and board-level risk quantification. Life sciences organizations must also protect intellectual property, clinical trial data, regulatory submissions, genomic datasets, pharmacovigilance platforms, and manufacturing continuity. Ultimately, the operating model should be organized around mission-critical outcomes: safe care, trusted data, resilient research, reliable reimbursement, secure devices, and accountable governance.
Key Takeaway
Healthcare and life sciences organizations need more than standard cybersecurity controls. They need resilience models designed around clinical continuity, patient safety, regulated research, complex identity environments, connected devices, and ecosystem dependency.
Explore Our Healthcare IT Transformation Services
P&C Global’s healthcare IT transformation services embed cyber resilience in connected care delivery.
The New Healthcare Cybersecurity Attack Surface
The healthcare cybersecurity attack surface has expanded because the healthcare operating model has expanded. Care delivery, research, administration, reimbursement, and patient engagement now rely on a distributed network of systems, vendors, devices, data flows, and interoperable digital health platforms.
Critical operations may depend on external clearinghouses, cloud-hosted applications, electronic health record vendors, specialty labs, pharmacy benefit managers, claims processors, remote patient monitoring platforms, AI tools, contract research organizations, device manufacturers, and outsourced service providers. As a result, third-party risk has become systemic operating risk.
Third-party involvement in breaches doubled from 15% to 30% across one major breach dataset, while healthcare, pharmaceuticals, and biotechnology recorded the highest volume of third-party breaches in a separate global third-party breach analysis. Together, those findings reinforce the same point: in healthcare and life sciences, third-party dependency is not a procurement issue alone. It is an operating risk.
The Change Healthcare attack demonstrated that third-party failures can rapidly become enterprise continuity failures, disrupting care delivery, payment flows, and operational control. AI in healthcare now adds another layer of exposure. As healthcare and life sciences organizations embed AI across diagnostics, clinical documentation, imaging, patient engagement, claims analysis, drug discovery, research, and administrative operations, they expand the points where sensitive data and critical workflows may be compromised. The risks extend beyond data leakage to include model misuse, prompt injection, compromised training data, opaque decision logic, shadow AI adoption, and vendor concentration.
Recent studies have shown why AI risk in healthcare requires more than conventional data governance. Medical LLMs have been shown to be vulnerable to prompt injection, poisoned fine-tuning, and malicious manipulation across disease prevention, diagnosis, and treatment tasks, while healthcare and life sciences organizations face growing exposure as sensitive data moves into AI-enabled workflows.
For life sciences organizations, exposure extends to intellectual property, proprietary models, trial data, genomic information, and scientific workflows. For providers, AI embedded in clinical operations raises questions about reliability, explainability, and cyber manipulation. For medtech firms, AI-enabled devices create cyber physical risks where software, connectivity, and clinical function converge.
The objective is not to slow digital transformation in healthcare, but to make it resilient by design through dependency mapping, data classification, vendor requirements, AI governance, recovery testing, and executive visibility into critical failure points.
Key Takeaway
The healthcare attack surface now extends across vendors, platforms, cloud environments, AI tools, claims infrastructure, research partners, connected devices, and data ecosystems that must be governed as part of enterprise resilience.
Medical Device Cybersecurity Is Patient Safety
Connected medical devices are part of the care environment, where medical device cybersecurity, device reliability, and patient safety are inseparable.
Infusion pumps, imaging systems, monitors, remote care devices, surgical technologies, diagnostic platforms, laboratory systems, and AI-enabled devices increasingly operate through networked infrastructure. They generate, transmit, receive, and act on sensitive data. Some also support decisions or interventions that directly affect care.
That creates a cyber-physical risk profile that traditional IT security models were not designed to manage. A vulnerable or unavailable device can delay diagnosis, force manual workarounds, disrupt treatment, and undermine clinical decision-making. The issue extends beyond device security to clinical capacity, operational continuity, and patient safety.
Modern hospitals depend on large fleets of connected medical devices across intensive care, diagnostics, monitoring, surgery, laboratory operations, and remote care. Estimates place the number of medical devices in U.S. hospitals at 10–15 million, with 10–15 connected devices per patient bed. As these devices generate, transmit, receive, and act on sensitive data, cybersecurity becomes inseparable from clinical reliability and patient safety.
Regulators are increasingly treating medical device cybersecurity as a full-lifecycle responsibility. The FDA’s cybersecurity guidance reflects this broader direction, emphasizing that security should be embedded throughout the device lifecycle—from design and development through deployment, post-market monitoring, vulnerability management, and ongoing maintenance—to help ensure devices remain resilient to evolving cyber threats. The implication is clear: device cybersecurity cannot begin after deployment. It must be built into the product and governed throughout its useful life.
For providers, device resilience requires more than asset inventory. Many healthcare environments depend on legacy devices that are difficult to patch, run outdated software, require manufacturer coordination, or cannot be taken offline without reducing clinical capacity. Effective governance must address risk classification, secure configuration, network segmentation, vulnerability management, manufacturer accountability, incident response, and retirement planning.
For medtech leaders, the same issue becomes a product strategy and market-access question. Secure-by-design expectations are now part of product quality, regulatory readiness, customer trust, and commercial credibility. Medical device cybersecurity is no longer only a technical requirement; it is part of the value proposition of connected care.
Key Takeaway
Medical device cybersecurity must be governed as both a patient safety and lifecycle resilience issue. Providers need visibility and control across deployed devices, while medtech firms must embed security into design, development, post-market monitoring, and product trust.
Life Sciences Cyber Resilience: Protecting the Innovation Pipeline
The life sciences risk profile differs from provider and payer environments. For pharma, biotech, medtech, and research organizations, cyber resilience is about protecting the evidence, assets, and operational continuity that move therapies, devices, and diagnostics from discovery to market.
Health-sector threat intelligence has highlighted growing concern around nation-state cyber-espionage targeting sensitive patient data and intellectual property. Recent incidents have also shown how attacks can reach clinical trial data and research operations. Novo Nordisk disclosed unauthorized access to pseudonymized clinical trial data, while contract research organization Inotiv reported a ransomware incident that disrupted business operations and access to internal systems. The implication for life sciences leaders is clear: cyber resilience protects not only current operations, but the evidence, assets, and continuity that support regulatory submissions, product launches, partnerships, and enterprise value.
Clinical trials depend on trusted data flows across sponsors, sites, contract research organizations, laboratories, patients, regulators, and analytics platforms. If data is altered, inaccessible, exfiltrated, or called into question, the consequences can extend to evidence quality, regulatory submissions, and confidence in research outcomes.
The same logic applies to genomic, biomarker, and proprietary research data. These datasets are highly sensitive, difficult to fully anonymize, and strategically valuable. As AI accelerates discovery and data reuse, access governance, data provenance, model oversight, and secure collaboration become central to resilience.
Manufacturing adds another dimension. Pharma and medtech production environments increasingly depend on connected operational technology, digital quality systems, supplier networks, and specialized equipment. A cyber event that disrupts manufacturing or quality release can affect product availability, supply commitments, regulatory obligations, and patient access.
Key Takeaway
In life sciences, cyber resilience protects the innovation pipeline. Leaders must safeguard clinical evidence, intellectual property, sensitive research data, manufacturing continuity, regulatory confidence, and the trust required to bring therapies, devices, and diagnostics to market.
Compliance Is the Baseline; Healthcare Continuity Is the Test
Compliance remains a necessary driver of cybersecurity in healthcare and life sciences, but it is not a measure of resilience. An organization may document required controls, complete risk assessments, and maintain backups while still lacking tested downtime procedures, visibility into third-party dependencies, or the ability to restore core workflows fast enough to protect care delivery, research continuity, or cash flow.
Compliance confirms that safeguards exist; resilience proves the organization can continue operating when systems are degraded or unavailable. Recent healthcare disruptions have demonstrated that documented controls alone are insufficient. Regulatory readiness must therefore be integrated with operational readiness.
Cyber preparedness should be tested through realistic scenarios: EHR downtime, imaging unavailability, pharmacy interruption, claims processing outages, device vulnerabilities, vendor compromise, ransomware containment, patient communications, and regulatory notification.
Boards should also require cyber risk quantification in enterprise terms. Instead of asking only how many critical vulnerabilities exist, leaders should ask: What would a 72-hour EHR outage cost? Which patient services would be delayed first? How long can clinical teams safely operate manually? Which vendors create single points of failure? What is the risk to trial timelines, payment flows, or regulatory submissions?
This moves cyber governance from technical oversight to strategic accountability. The goal is not unlimited cyber spending. It is disciplined investment in the controls, rehearsals, recovery capabilities, and governance mechanisms most directly tied to patient, financial, research, and operational resilience.
Key Takeaway
Compliance remains necessary, but it is not a proxy for resilience. Healthcare and life sciences leaders must test whether critical care, research, reimbursement, and regulatory operations can continue when digital infrastructure is compromised.
A C-Suite Playbook for Healthcare Cyber Resilience
Healthcare cybersecurity and cyber resilience cannot be achieved through technology alone. It requires an operating model that connects governance, clinical continuity, third-party dependency, identity, data, devices, incident response, and recovery. The goal is not simply to harden systems, but to ensure the organization can continue its most critical work when digital infrastructure is impaired.
1. Define what must continue
Healthcare and life sciences organizations should begin by identifying the workflows most essential to patient care, research continuity, reimbursement, manufacturing, and regulatory obligations. Emergency care, medication administration, diagnostics, pharmacy operations, prior authorization, claims submission, trial data capture, manufacturing quality systems, and regulatory reporting should be mapped to the systems, vendors, data, users, devices, and manual workarounds required to keep them functioning.
2. Translate disruption into enterprise impact.
Boards and executive committees need more than technical metrics. They need to understand how plausible disruption could affect patient access, clinical throughput, liquidity, trial timelines, manufacturing continuity, regulatory exposure, and trust. Cyber risk quantification should help leaders compare investments, prioritize controls, and focus resilience spending on the failure points that matter most.
3. Build resilience into operating controls.
Continuity depends on more than recovery plans. It requires third-party dependency reviews, identity governance, device security programs, AI data controls, backup and restoration testing, clinical downtime procedures, and cyber incident response protocols designed around healthcare-specific scenarios.
4. Prove readiness before disruption occurs.
Tabletop exercises and recovery tests should include clinical, operational, financial, legal, compliance, technology, communications, research, and product leaders. The objective is to test whether the organization can make decisions under pressure, restore priority workflows, manage vendor failure, communicate with stakeholders, and sustain care or research operations while systems are degraded.
5. Assign executive accountability.
The Chief Information Security Officer (CISO) plays a critical role, but the mandate cannot sit with security alone. Cyber resilience should be visible in board oversight, enterprise risk management, capital planning, digital transformation, M&A, vendor strategy, product development, and crisis preparedness.
Key Takeaway
Cyber resilience is an enterprise operating discipline. Leading organizations will define what must continue, quantify the impact of disruption, build resilience into operating controls, test readiness before crisis, and assign clear executive accountability across care, research, revenue, and trust.
Healthcare Resilience by Design Is the New Standard
Healthcare and life sciences organizations are now digital, connected, data-driven, and ecosystem-dependent. That transformation creates opportunity, but it also introduces new points of fragility.
The strategic task is not to slow digital transformation, but to make it resilient by design. That requires moving beyond healthcare cybersecurity as breach prevention or compliance management towards operating models that sustain care delivery, protect research, preserve financial continuity, secure connected devices, maintain trusted data, and respond effectively to disruption.
The most resilient organizations will not claim immunity from cyber risk. They will understand critical dependencies, quantify disruption in enterprise terms, rehearse response, and make resilience a leadership discipline.
Cyber resilience is patient resilience—and research, revenue, product, and trust resilience as well. In a digitally connected health system, it has become a defining enterprise capability for C-level leaders.
